Andrzej Jakubowiak, MD, PhD | Authors

Articles

Safety Results for Daratumumab Combined With Carfilzomib, Lenalidomide, and Dexamethasone in Multiple Myeloma

June 15, 2017

Andrzej Jakubowiak, MD, PhD, professor of Medicine, University of Chicago Medicine, discusses safety results from an open label, phase 1b trial exploring daratumumab (Darzalex) combined with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone in patients with newly diagnosed multiple myeloma.

Toxicity Profile of Panobinostat as seen in the PANORAMA Trial

August 22, 2014

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.